• From S-Phase Signal to Vascular Mechanism

  2026-08-23

  A translational framework for using EdU-based flow cytometry to connect DNA synthesis with endothelial–smooth muscle crosstalk, hypoxia pulmonary hypertension, genotoxicity testing, and pharmacodynamic decision-making.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-08-22

  The reference study identifies circulating moesin (MSN) as a severity-associated biomarker of endothelial injury in sepsis and links its elevation to Rock1/MLC and NF-κB signaling. By combining patient measurements, mouse models, and endothelial-cell experiments, the work connects clinical association with a plausible mechanism of vascular barrier disruption.

• Exo1 in Exocytosis Assay Design

  2026-08-22

  Exo1 enables acute, mechanistically distinct membrane trafficking inhibition for Golgi–ER transport, ARF1 biology, and exocytosis assays. Used with appropriate controls, it can also help separate secretion-dependent effects from tumor extracellular vesicle behavior without being misrepresented as a direct or clinically validated metastasis therapy.

• OSMI-1: O-GlcNAc Transferase Inhibitor Guide

  2026-08-21

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor that reduces protein O-GlcNAcylation through OGT inhibition. Its reported biochemical potency, cellular viability effect, zebrafish acute-toxicity benchmarks, and formulation limits support controlled mechanistic research rather than direct therapeutic interpretation.

• Cimetidine in BBB and H2R Research Workflows

  2026-08-20

  Cimetidine supports a practical two-track workflow: mechanistic H2 receptor studies in gastrointestinal cancer models and controlled transport testing in surrogate blood-brain barrier assays. Its documented solubility and distinct pharmacological profile make it useful for assay development, provided permeability, recovery, and receptor effects are interpreted separately.

• Temozolomide Workflows for ATRX-Deficient Glioma

  2026-08-20

  Build reproducible Temozolomide assays around DNA damage, ATRX status, and rational RTK or PDGFR inhibitor combinations. This guide emphasizes reagent handling, dose–time design, genotype-aware controls, and troubleshooting for translational glioma research.

• Hesperadin: Aurora B Kinase Inhibitor Guide

  2026-08-19

  Hesperadin is an ATP-competitive Aurora B kinase inhibitor that disrupts histone H3 Ser-10 phosphorylation and mitotic chromosome behavior. Its biochemical potency, HeLa-cell phenotype, solvent profile, and checkpoint relevance make it a useful research tool rather than a clinical treatment claim.

• CH 223191 Workflows for AhR Mechanistic Studies

  2026-08-19

  CH 223191 enables controlled interrogation of AhR activity across dioxin toxicology, epithelial differentiation, and microbiota-linked intestinal repair models. This practical workflow connects concentration planning, CYP1A1 readouts, organoid assays, and troubleshooting for reproducible environmental toxicology research.

• Adefovir: From HBV Assays to Renal Risk

  2026-08-18

  Adefovir and GS-0393 offer a powerful model for studying HBV DNA polymerase inhibition and OAT1-mediated renal handling. This article connects antiviral assay design with a clinically important, evidence-based framework for detecting phosphate-wasting toxicity and interpreting translational exposure.

• Canagliflozin: SGLT2 Inhibitor Research Guide

  2026-08-18

  Canagliflozin is a selective SGLT2 inhibitor that suppresses renal glucose reabsorption and increases urinary glucose excretion. Recent mouse data link treatment with proximal tubular mitochondrial remodeling, improved bioenergetics in males, and reduced albuminuria.

• A20, Oxidized DNA, and Acute Kidney Injury

  2026-08-17

  The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and shows that A20 limits this response by restraining STING signaling and NLRP3-mediated pyroptosis. Its mechanistic and peptide-validation data position the A20–NEK7 interaction as a potential therapeutic entry point, while also providing a framework for interpreting inflammasome modulation in related disease models.

• Berberine Hydrochloride: AMPK Research Workflows

  2026-08-17

  Berberine hydrochloride is a defined chemical probe for connecting AMPK-driven metabolic regulation with LDL receptor, mitochondrial, oxidative-stress, and cancer readouts. This workflow shows how to move from reproducible DMSO stocks to cell-based assays, cardiotoxicity models, and troubleshooting decisions without overextending evidence from botanical extracts.

• Sitagliptin Phosphate Monohydrate in Gut Signaling

  2026-08-16

  Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor that can help separate incretin-dependent glucose regulation from intestinal stretch signaling. This article translates recent gut mechanosensation findings into practical assay and study-design decisions.

• Hypoxia and Immunometabolism in the Tumor Microenvironment

  2026-08-15

  This 2025 review frames tumor hypoxia and immunometabolism as a reciprocal system in which oxygen limitation, nutrient competition, and HIF signaling reshape both malignant and immune-cell behavior. Its main practical implication is that tumor progression and therapeutic response should be interpreted through coordinated metabolic, immune, and redox measurements rather than through isolated molecular endpoints.

• 3-Deazaneplanocin (DZNep) in Cancer Research

  2026-08-14

  3-Deazaneplanocin (DZNep) connects S-adenosylhomocysteine hydrolase inhibition with functional EZH2 suppression, making it useful for apoptosis induction in AML cells, hepatocellular carcinoma research, and cancer stem cell targeting. This workflow-driven guide covers dose design, epigenetic readouts, model stratification, and troubleshooting for reproducible experiments.

8024 records 1/535 page Next 12345 下5页 Last page